144 related articles for article (PubMed ID: 36334155)
1. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Maßmann M; Treckmann J; Markus P; Schumacher B; Albers D; Ting S; Mende B; Roehrle J; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Schmid KW; Baba H; Siveke JT; Paul A; Schildhaus HU; Schuler M; Wiesweg M; Kasper S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5085-5094. PubMed ID: 36334155
[TBL] [Abstract][Full Text] [Related]
2. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
3. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
[TBL] [Abstract][Full Text] [Related]
4. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Markus M; Abendroth A; Noureddine R; Paul A; Breitenbuecher S; Virchow I; Schmid KW; Markus P; Schumacher B; Wiesweg M; Wendling J; Mende B; Siveke JT; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):579-591. PubMed ID: 32839836
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study.
Liguori C; Copparoni C; Felicetti C; Pecci F; Lupi A; Pinterpe G; Berardi R; Giampieri R
Curr Oncol; 2023 Jan; 30(1):1032-1045. PubMed ID: 36661728
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
[No Abstract] [Full Text] [Related]
7. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Cho H; Yoo C; Kim KP; Jeong JH; Kang J; Chang HM; Lee SS; Park DH; Song TJ; Lee SK; Kim MH; Lee HC; Lim YS; Kim KM; Shim JH; Hwang S; Song GW; Moon DB; Lee JH; Lee YJ; Ryoo BY
Invest New Drugs; 2018 Jun; 36(3):496-502. PubMed ID: 29192354
[TBL] [Abstract][Full Text] [Related]
10. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma.
Fu X; Li T; Dai Y; Li J
BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297
[TBL] [Abstract][Full Text] [Related]
11. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection.
Zhang Y; Shi SM; Yang H; Yang LX; Wang Z; Li XD; Yin D; Shi YH; Cao Y; Dai Z; Zhou J; Chen Q
J Cancer; 2019; 10(2):494-503. PubMed ID: 30719145
[TBL] [Abstract][Full Text] [Related]
12. The pretherapeutic systemic inflammation score is a prognostic predictor for elderly patients with oesophageal cancer: a case control study.
Huang C; Wang M; Chen L; Wang H; Huang D; Shi J; Zhang W; Tian Y; Zhu Y
BMC Cancer; 2023 Jun; 23(1):505. PubMed ID: 37270496
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
14. Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.
Chiu TJ; Chen YJ; Kuo FY; Chen YY
PLoS One; 2020; 15(12):e0240791. PubMed ID: 33306714
[TBL] [Abstract][Full Text] [Related]
15. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
18. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.
Sellers CM; Uhlig J; Ludwig JM; Stein SM; Kim HS
Cancer Med; 2019 Oct; 8(13):5916-5929. PubMed ID: 31429524
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of lymphocyte-to-C-reactive protein score in patients undergoing surgical resection for intrahepatic cholangiocarcinoma: A comparative study of major representative inflammatory / immunonutritional markers.
Noguchi D; Kuriyama N; Nakagawa Y; Maeda K; Shinkai T; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Sakurai H; Mizuno S
PLoS One; 2021; 16(1):e0245946. PubMed ID: 33507925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]